Moisand Fitzgerald Tamayo’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9	Closed	-$1K	–	716
2022 Q2	$1K	Sell	9 -8	-47%	-$637	﹤0.01%	476
2022 Q1	$1K	Buy	17 +4	+31%	+$335	﹤0.01%	442
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	357
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	347
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	380
2021 Q1	$1K	Hold	13	–	–	﹤0.01%	322
2020 Q4	$1K	Hold	13	–	–	﹤0.01%	320
2020 Q3	$1K	Hold	13	–	–	﹤0.01%	297
2020 Q2	$2K	Buy	+13	New	+$1.29K	﹤0.01%	263

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Moisand Fitzgerald Tamayo's BMRN Position: Q3 2022 in Review

Moisand Fitzgerald Tamayo sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 9 shares — an estimated $1K sold.

Moisand Fitzgerald Tamayo first reported a position in BMRN in Q2 2020 and held it in 9 quarters. The position peaked at $2K in Q2 2020. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Moisand Fitzgerald Tamayo reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Moisand Fitzgerald Tamayo sold 9 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1K.
Moisand Fitzgerald Tamayo first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Moisand Fitzgerald Tamayo's BioMarin Pharmaceuticals position peaked at $2K in Q2 2020.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q3 2022, filed 26 Oct 2022.